SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 12.71% to Rs. 13043.10 millions for the quarter ended March 2022 as compared to Rs. 11572.40 millions during the corresponding quarter last year.The Company has registered profit of Rs. 2513.70  millions for the quarter ended March 2022, a growth of 8.77%  over Rs. 2311.10 millions millions achieved in the corresponding quarter of last year.The company reported a degrowth in operating Profit to 3029.00 millions from 3250.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 13043.10 11572.40 12.71 49966.00 50514.40 -1.09 49966.00 50514.40 -1.09
Other Income 116.00 247.40 -53.11 499.80 835.20 -40.16 499.80 835.20 -40.16
PBIDT 3029.00 3250.20 -6.81 11044.30 15819.70 -30.19 11044.30 15819.70 -30.19
Interest 59.20 21.40 176.64 166.70 127.70 30.54 166.70 127.70 30.54
PBDT 2969.80 3228.80 -8.02 10877.60 15692.00 -30.68 10877.60 15692.00 -30.68
Depreciation 459.50 418.40 9.82 1793.10 1526.00 17.50 1793.10 1526.00 17.50
PBT 2510.30 2810.40 -10.68 9084.50 14166.00 -35.87 9084.50 14166.00 -35.87
TAX -3.40 499.30 -100.68 1144.50 2412.10 -52.55 1144.50 2412.10 -52.55
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 2513.70 2311.10 8.77 7940.00 11753.90 -32.45 7940.00 11753.90 -32.45
Equity 393.10 393.10 0.00 393.10 393.10 0.00 393.10 393.10 0.00
PBIDTM(%) 23.22 28.09 -17.31 22.10 31.32 -29.42 22.10 31.32 -29.42

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×